Cardiac Angiosarcoma International Registry

NCT06715579 | Recruiting DMC

• 1 other identifier: IMMONC0020
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are:

1. 1.Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database.
2. 2.Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma.
3. 3.Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices.
4. 4.Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.

Conditions

Cardiac Angiosarcoma

Keywords

Cardiac Angiosarcoma; Angiosarcoma; Hemangiosarcoma; Epithelioid Hemangiosarcoma; Primary Cardiac Sarcoma

Outcome Measures

Primary Outcomes (1)

• 6-month overall survival

  6 months

Secondary Outcomes (8)

• 1-year overall survival

  1 year

• 6-month progression free survival

  6 months

• 1-year progression free survival

  1 year

• 3-year progression free survival

  3 years

• 6-month event-free survival

  6 months

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients diagnosed with Cardiac Angiosarcoma

You may qualify if:

• Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma.
• Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035.
• Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations.
• Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes.
• Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry.
• Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis.
• Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts.

You may not qualify if:

• Patients who decline to provide informed consent.
• Cases where cardiac involvement is secondary to another primary malignancy

Sponsors & Collaborators

• Immune Oncology Research Institute: lead

Study Sites (1)

Yeolyan Hematology and Oncology Center

Yerevan, 0014, Armenia

RECRUITING

MeSH Terms

Conditions

Hemangiosarcoma

Condition Hierarchy (Ancestors)

Sarcoma; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Vascular Tissue

Study Officials

• Shushan Hovsepyan, MD

  Immune Oncology Research Institute, Yerevan, Armenia

  PRINCIPAL INVESTIGATOR

• Amalya Sargsyan, MD

  Immune Oncology Research Institute, Yerevan, Armenia

  STUDY CHAIR

• Ruzanna Papyan, MD

  Immune Oncology Research Institute, Yerevan, Armenia

  STUDY DIRECTOR

Central Study Contacts

Aharon Tsaturyan, MD

CONTACT

+374 99190152; aharon3tsaturyan@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 28, 2024
• First Posted: December 4, 2024
• Study Start: May 1, 2025
• Primary Completion (Estimated): May 1, 2035
• Study Completion (Estimated): May 1, 2035
• Last Updated: February 18, 2026

Record last verified: 2026-02

Locations

AR (1)